Fecal Microbiota Transplantation: Procedure and Recovery (Mayo Clinic)

For inflammatory bowel disease (IBD), FMT shows 20-30% remission rates versus 5-10% with placebo. A pilot study at Hôpital Saint-Antoine tested FMT after cortisone treatment to maintain remission, showing reduced relapse rates. For irritable bowel syndrome (IBS), results are contradictory with some studies showing positive effects and others showing symptom worsening. For metabolic syndrome, some studies show improvement but results remain preliminary. These findings indicate that FMT's effectiveness varies significantly across conditions, with the microbiote playing different roles in each disease.

Modern humans have disconnected from nature, losing contact with animals and natural environments. This disconnection contributes to increased allergies, autoimmune diseases, and digestive problems. Children who play outdoors, have contact with animals, and engage in 'dirty' play develop stronger immune systems and fewer allergies. Excessive hygiene (antibacterial soaps, frequent disinfection) destroys beneficial microbiota and weakens immune function. Fecal microbiota transplantation (FMT) involves transferring healthy microbiota from a donor to a recipient with dysbiosis. The process involves cleaning and preparing the donor's fecal material. Methods include colonoscopy, enemas, and oral capsules. FMT is being studied for conditions including IBS, inflammatory bowel disease, obesity, metabolic disorders, depression, anxiety, and autism. It has been approved for severe ulcerative colitis in some countries.

IBD represents the next frontier for microbiome-based therapies. Healthy individuals show 80% Bacteroidetes and 20% Firmicutes, while IBD patients reverse this ratio. Germ-free mice with genetic predispositions to colitis do not develop inflammation without microbial exposure, proving commensals are necessary for disease expression. Four randomized trials evaluated FMT for ulcerative colitis: single-donor studies showed 24% remission versus 5% placebo; pooled donor studies achieved 28% remission versus 9% placebo. Mount Sinai plans to replicate successful Australian capsule-based protocols while investigating antibiotic pretreatment effects. Over 265 clinical trials worldwide now explore FMT for graft-versus-host disease, hepatic encephalopathy, PSC, and immune checkpoint inhibitor colitis.

FMT applications are expanding beyond IBD to include chronic constipation, metabolic syndrome, arteriosclerosis, and multiple sclerosis. Modern lifestyle factors including high-fat diets and reduced plant fiber intake contribute to declining gut microbiota diversity, increasing disease prevalence. Evidence hierarchy requires randomized controlled trials with statistical significance (p<0.05) for treatment recognition. FMT is being practiced as both clinical treatment and research tool, with practitioners contributing to evidence generation through case sharing and collaboration with research organizations.

Fecal microbiota transplantation (FMT) represents a paradigm shift in treating diseases by restoring the entire gut microbiome ecosystem rather than targeting single pathogens; while FMT has proven highly effective for antibiotic-resistant C. diff infections, ongoing clinical trials are exploring its potential for inflammatory bowel disease, irritable bowel syndrome, and Crohn's disease, with researchers investigating whether specific bacterial profiles or the complete microbial community offers superior therapeutic outcomes.

Fecal microbiota transplants (FMT) are FDA-approved for C. difficile infections, where patients can experience months of terrible diarrhea that resolves within hours after FMT. However, FMT from other sources carries risks of transmitting pathogens like E. coli, requiring screening and use of banked products. The FDA approval of Rebiota has decreased research-grade poop pill availability. The future of microbial therapeutics lies in defined combinations of 20-175 strains that have been cultivated, defined, and can be administered. Current probiotics contain only a few species, while fecal transplants contain hundreds of unknown strains. The goal is defined therapeutics that deliver benefits without unpredictability.

This lecture presents two complementary reductionist approaches for developing rationally designed microbial therapeutics: (1) the top-down approach identifies effector bacteria by starting with a specific phenotype (like regulatory T-cell induction) and narrowing down the microbiota to obtain functionally relevant minimal bacterial consortia, which has led to clinical candidates for treating inflammatory bowel disease and cancer; and (2) the bottom-up approach starts with metabolites identified through metabolomic analysis to discover beneficial bacteria, exemplified by identifying Parabacteroides distasonis that degrades trypsin and protects against viral infections, and isoHCA-producing bacteria from centenarian microbiota that inhibit gram-positive pathogens. These strategies aim to replace fecal microbiota transplantation with well-characterized bacterial strains for safer and more predictable therapeutic interventions.

The FDA approvals of Rebiota and Vowst marked the first time beneficial bacteria were packaged as FDA-approved medicine. Vowst's oral spore-based capsules eliminate the need for colonoscopies. Infant Bacterial Therapeutics achieved 27% reduction in mortality for premature infants at risk for necrotizing enterocolitis. FMT has enhanced cancer immunotherapy responses in melanoma patients resistant to PD1 inhibitors. Smart toilets now analyze microbiomes automatically using spray erosion technology. Companies like Viome use RNA sequencing to identify active bacteria and provide personalized recommendations. The microbiome therapeutics market is growing at over 17% annually, with over 100 products in clinical trials. Major pharmaceutical companies are developing their own programs or acquiring microbiome startups, signaling mainstream adoption of this revolutionary approach to human health.

Clinical trials using defined bacterial consortia have demonstrated 64% reduction in atopic dermatitis risk and 77% reduction in food allergy risk when administered during the first year of life. This represents a shift from treating existing allergies to preventing them through microbiome-based interventions. Next-generation therapeutics move beyond fecal transplantation toward rationalized approaches identifying specific bacterial strains responsible for beneficial metabolites and introducing them as personalized therapy. This addresses limitations of fecal transplantation by targeting missing functions in the microbiome, similar to gene therapy but applied to the microbiome as an organ-like system. Collaboration between microbiome researchers, immunologists, and clinicians enables understanding mechanisms and creating safe, precise therapies for the future.

FDA regulation balances safety concerns with therapeutic access for C. difficile infection. Initial pathogen transmission fears led to discretionary oversight requiring IND applications except for C. difficile. Approved products now exist, while biobanks require INDs. The AGA maintains an FMT registry tracking over 1,000 individuals with long-term follow-up; no significant safety signals emerged in initial follow-up periods. The field evolves from whole-fecal transplant toward defined microbial consortia—specific combinations of laboratory-grown organisms targeting particular diseases with greater precision. This progression reflects broader trends toward personalized, mechanism-based treatments. The FDA's new designation for Live Biotherapeutic Products acknowledges this unique therapeutic category. Beyond transplantation, bacteriophage therapy targeting pathogenic bacteria shows promise for conditions like alcoholic liver disease and cystic fibrosis, representing the next frontier in microbiota-based medicine.

The gut serves as a central hub connecting multiple body systems through the gut-brain axis. The gut produces more serotonin than the brain and releases oxytocin through the vagus nerve, directly influencing mood and stress responses. Compromised gut barrier allows bacterial byproducts like LPS and PGLYRP to leak into the bloodstream, triggering systemic inflammation linked to neuroinflammation and conditions like autism. Children with autism show higher PGLYRP levels and corresponding brain inflammation. This explains why gut health impacts seemingly unrelated conditions—from immune function and metabolism to mental health—demonstrating the microbiome's role as an invisible but essential organ coordinating whole-body physiology.

The gut-brain axis creates a bidirectional communication system where gut health directly influences mental health. Inflammation from a disrupted microbiome can affect neurotransmitter production (serotonin, dopamine, noradrenaline) and brain function. Research shows that gut microbiota influences anxiety and depression through multiple pathways: the vagus nerve, the HPA axis, and immune signaling. The speaker emphasizes that this connection provides new opportunities for treating mental health conditions through dietary interventions and probiotic supplementation. This represents a paradigm shift in mental health treatment, offering new options for patients who don't respond to conventional therapies.

The gut and brain communicate bidirectionally through the vagus nerve, which descends from the neck through the chest and abdominal cavity. The enteric nervous system contains billions of neurons and functions as a 'second brain' with its own neurotransmitter production. The gut produces 90% of the body's serotonin, suggesting depression may originate in the gut rather than the brain. Electrical vagus nerve stimulation treats medication-resistant depression. Gut microbiota significantly influences behavior through evolutionary mechanisms—transferring bacteria between mice with different personalities changes their behavior. Maternal high-fat diets alter offspring gut microbiota, increasing autism risk. Bacteria may manipulate host behavior to facilitate their own transmission. Gut bacteria control food preferences by manipulating the brain's reward system. Maintaining microbiota diversity prevents any single species from dominating. A study of 120,000 people found yogurt to be the most effective food for weight loss. Psychobiotics (beneficial bacteria) show promise for treating depression and anxiety, with Iranian research demonstrating significant improvement in depression scores after 8 weeks of bacterial supplementation.

The gut contains 2kg of bacteria, more than the brain's weight. These bacteria produce neurotransmitters that travel through the vagus nerve to the brain, influencing food cravings, mood, and sleep. Approximately 90% of serotonin is produced in the gut by bacteria. Damaged microbiota causes anxiety, irritability, and stress-eating behaviors that further damage the gut. Antibiotics destroy 50% of gut bacteria, sugar feeds pathogenic bacteria and Candida (producing 70+ toxins), chlorine in tap water damages microbiota daily, and stress hormones suppress beneficial bacteria while promoting harmful ones.

The gut-brain axis is a bidirectional communication network connecting the gastrointestinal tract with the central nervous system, where gut microbiota produces neurotransmitters like serotonin (90% of the body's supply), modulates immune function, and influences mental health; dysbiosis (microbial imbalance) can lead to both gastrointestinal symptoms and psychiatric conditions such as anxiety and depression, while chronic stress and poor lifestyle choices can further disrupt this axis, making integrated treatment approaches involving diet, probiotics, and psychological support essential for managing these interconnected conditions.